On 26 February 2019, orphan designation (EU/3/19/2143) was granted by the European Commission to Pharma Mar S.A., Spain, for lurbinectedin for the treatment of small cell lung cancer.
|Disease / condition||
Treatment of small cell lung cancer
|Date of decision||
|Orphan decision number||
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.